nodes	percent_of_prediction	percent_of_DWPC	metapath
Melphalan—SLC7A5—Basigin interactions—ATP1B2—esophageal cancer	0.0334	0.144	CbGpPWpGaD
Melphalan—SLC7A5—Aryl Hydrocarbon Receptor Pathway—ALDH3A1—esophageal cancer	0.0288	0.124	CbGpPWpGaD
Melphalan—Pulmonary toxicity—Cisplatin—esophageal cancer	0.0263	0.0393	CcSEcCtD
Melphalan—Extravasation—Carboplatin—esophageal cancer	0.0233	0.0348	CcSEcCtD
Melphalan—SLC22A3—Abacavir transmembrane transport—ABCB1—esophageal cancer	0.0215	0.0924	CbGpPWpGaD
Melphalan—Acute leukaemia—Cisplatin—esophageal cancer	0.0209	0.0312	CcSEcCtD
Melphalan—Ureteric obstruction—Methotrexate—esophageal cancer	0.0199	0.0298	CcSEcCtD
Melphalan—Skin necrosis—Cisplatin—esophageal cancer	0.0171	0.0255	CcSEcCtD
Melphalan—Pulmonary toxicity—Methotrexate—esophageal cancer	0.0144	0.0215	CcSEcCtD
Melphalan—Myelosuppression—Cisplatin—esophageal cancer	0.0127	0.019	CcSEcCtD
Melphalan—Infertility—Methotrexate—esophageal cancer	0.0125	0.0187	CcSEcCtD
Melphalan—SLC7A5—Aryl Hydrocarbon Receptor Pathway—NFE2L2—esophageal cancer	0.0125	0.0539	CbGpPWpGaD
Melphalan—SLC22A3—Abacavir transport and metabolism—ABCB1—esophageal cancer	0.0124	0.0531	CbGpPWpGaD
Melphalan—SLC7A5—epithelium—esophageal cancer	0.0123	0.144	CbGeAlD
Melphalan—Arterial thrombosis—Methotrexate—esophageal cancer	0.0122	0.0182	CcSEcCtD
Melphalan—Leukaemia—Methotrexate—esophageal cancer	0.0122	0.0182	CcSEcCtD
Melphalan—SLC7A5—bronchus—esophageal cancer	0.0121	0.142	CbGeAlD
Melphalan—SLC7A5—smooth muscle tissue—esophageal cancer	0.0118	0.139	CbGeAlD
Melphalan—SLC7A5—Cell surface interactions at the vascular wall—ATP1B2—esophageal cancer	0.0111	0.0477	CbGpPWpGaD
Melphalan—SLC7A5—trachea—esophageal cancer	0.0109	0.128	CbGeAlD
Melphalan—Rales—Capecitabine—esophageal cancer	0.0107	0.016	CcSEcCtD
Melphalan—Febrile neutropenia—Cisplatin—esophageal cancer	0.00992	0.0148	CcSEcCtD
Melphalan—Lymphoma—Methotrexate—esophageal cancer	0.00937	0.014	CcSEcCtD
Melphalan—Skin necrosis—Methotrexate—esophageal cancer	0.00937	0.014	CcSEcCtD
Melphalan—SLC7A5—digestive system—esophageal cancer	0.00934	0.11	CbGeAlD
Melphalan—SLC7A5—Aryl Hydrocarbon Receptor Pathway—CYP1B1—esophageal cancer	0.00869	0.0373	CbGpPWpGaD
Melphalan—Rales—Methotrexate—esophageal cancer	0.00798	0.0119	CcSEcCtD
Melphalan—SLC7A5—lung—esophageal cancer	0.0078	0.0918	CbGeAlD
Melphalan—Impaired healing—Methotrexate—esophageal cancer	0.00757	0.0113	CcSEcCtD
Melphalan—Pulmonary fibrosis—Methotrexate—esophageal cancer	0.00744	0.0111	CcSEcCtD
Melphalan—SLC22A3—smooth muscle tissue—esophageal cancer	0.00734	0.0864	CbGeAlD
Melphalan—Febrile neutropenia—Capecitabine—esophageal cancer	0.00731	0.0109	CcSEcCtD
Melphalan—Infection—Carboplatin—esophageal cancer	0.00721	0.0108	CcSEcCtD
Melphalan—Ibuprofen—BCL2—esophageal cancer	0.00708	0.543	CrCbGaD
Melphalan—Respiratory distress—Capecitabine—esophageal cancer	0.00692	0.0103	CcSEcCtD
Melphalan—Extravasation—Cisplatin—esophageal cancer	0.00684	0.0102	CcSEcCtD
Melphalan—Interstitial pneumonia—Methotrexate—esophageal cancer	0.00677	0.0101	CcSEcCtD
Melphalan—SLC7A5—Aryl Hydrocarbon Receptor Pathway—BAX—esophageal cancer	0.00677	0.0291	CbGpPWpGaD
Melphalan—Bone marrow depression—Capecitabine—esophageal cancer	0.00651	0.00973	CcSEcCtD
Melphalan—Hyperuricaemia—Cisplatin—esophageal cancer	0.00643	0.00961	CcSEcCtD
Melphalan—Ulcer—Cisplatin—esophageal cancer	0.00631	0.00942	CcSEcCtD
Melphalan—Pain—Carboplatin—esophageal cancer	0.0062	0.00927	CcSEcCtD
Melphalan—Blood uric acid increased—Cisplatin—esophageal cancer	0.00607	0.00908	CcSEcCtD
Melphalan—Hepatocellular injury—Cisplatin—esophageal cancer	0.00597	0.00891	CcSEcCtD
Melphalan—Skin exfoliation—Cisplatin—esophageal cancer	0.00569	0.00851	CcSEcCtD
Melphalan—Skin ulcer—Capecitabine—esophageal cancer	0.00565	0.00844	CcSEcCtD
Melphalan—Neuropathy—Cisplatin—esophageal cancer	0.0056	0.00837	CcSEcCtD
Melphalan—Tingling sensation—Capecitabine—esophageal cancer	0.00547	0.00817	CcSEcCtD
Melphalan—SLC22A3—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC39A6—esophageal cancer	0.00545	0.0234	CbGpPWpGaD
Melphalan—Febrile neutropenia—Methotrexate—esophageal cancer	0.00544	0.00813	CcSEcCtD
Melphalan—SLC7A5—lymph node—esophageal cancer	0.00533	0.0628	CbGeAlD
Melphalan—SLC22A3—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC30A7—esophageal cancer	0.00499	0.0214	CbGpPWpGaD
Melphalan—SLC7A5—SLC-mediated transmembrane transport—SLC39A6—esophageal cancer	0.00487	0.0209	CbGpPWpGaD
Melphalan—Bone marrow depression—Methotrexate—esophageal cancer	0.00485	0.00725	CcSEcCtD
Melphalan—SLC22A3—lung—esophageal cancer	0.00484	0.057	CbGeAlD
Melphalan—Liver disorder—Methotrexate—esophageal cancer	0.0048	0.00718	CcSEcCtD
Melphalan—Haemolytic anaemia—Cisplatin—esophageal cancer	0.0048	0.00717	CcSEcCtD
Melphalan—Renal failure acute—Cisplatin—esophageal cancer	0.00469	0.00701	CcSEcCtD
Melphalan—Ulcer—Capecitabine—esophageal cancer	0.00465	0.00695	CcSEcCtD
Melphalan—Interstitial lung disease—Methotrexate—esophageal cancer	0.00462	0.00691	CcSEcCtD
Melphalan—SLC7A5—Hemostasis—CAPZA1—esophageal cancer	0.00455	0.0195	CbGpPWpGaD
Melphalan—SLC7A5—SLC-mediated transmembrane transport—SLC30A7—esophageal cancer	0.00445	0.0191	CbGpPWpGaD
Melphalan—Injection site reaction—Capecitabine—esophageal cancer	0.00437	0.00653	CcSEcCtD
Melphalan—Hyponatraemia—Cisplatin—esophageal cancer	0.00435	0.0065	CcSEcCtD
Melphalan—Skin ulcer—Methotrexate—esophageal cancer	0.0042	0.00628	CcSEcCtD
Melphalan—Skin exfoliation—Capecitabine—esophageal cancer	0.0042	0.00627	CcSEcCtD
Melphalan—Neuropathy—Capecitabine—esophageal cancer	0.00413	0.00617	CcSEcCtD
Melphalan—Mouth ulceration—Capecitabine—esophageal cancer	0.00398	0.00594	CcSEcCtD
Melphalan—Neoplasm—Capecitabine—esophageal cancer	0.00398	0.00594	CcSEcCtD
Melphalan—Extravasation—Methotrexate—esophageal cancer	0.00375	0.00561	CcSEcCtD
Melphalan—Pancytopenia—Cisplatin—esophageal cancer	0.00355	0.00531	CcSEcCtD
Melphalan—Haemolytic anaemia—Capecitabine—esophageal cancer	0.00354	0.00528	CcSEcCtD
Melphalan—Hyperuricaemia—Methotrexate—esophageal cancer	0.00353	0.00527	CcSEcCtD
Melphalan—Ulcer—Methotrexate—esophageal cancer	0.00346	0.00517	CcSEcCtD
Melphalan—Renal failure acute—Capecitabine—esophageal cancer	0.00346	0.00517	CcSEcCtD
Melphalan—Atrial fibrillation—Capecitabine—esophageal cancer	0.00337	0.00503	CcSEcCtD
Melphalan—Vasculitis—Methotrexate—esophageal cancer	0.00335	0.00501	CcSEcCtD
Melphalan—Blood uric acid increased—Methotrexate—esophageal cancer	0.00333	0.00498	CcSEcCtD
Melphalan—SLC22A3—lymph node—esophageal cancer	0.00331	0.039	CbGeAlD
Melphalan—Neuropathy peripheral—Cisplatin—esophageal cancer	0.00327	0.00489	CcSEcCtD
Melphalan—SLC7A5—Aryl Hydrocarbon Receptor Pathway—EP300—esophageal cancer	0.00326	0.014	CbGpPWpGaD
Melphalan—Stomatitis—Cisplatin—esophageal cancer	0.00325	0.00486	CcSEcCtD
Melphalan—Hyponatraemia—Capecitabine—esophageal cancer	0.0032	0.00479	CcSEcCtD
Melphalan—Cystitis noninfective—Methotrexate—esophageal cancer	0.0032	0.00478	CcSEcCtD
Melphalan—Cystitis—Methotrexate—esophageal cancer	0.00316	0.00472	CcSEcCtD
Melphalan—Hepatobiliary disease—Cisplatin—esophageal cancer	0.00316	0.00472	CcSEcCtD
Melphalan—Skin exfoliation—Methotrexate—esophageal cancer	0.00313	0.00467	CcSEcCtD
Melphalan—Cardiac arrest—Capecitabine—esophageal cancer	0.00304	0.00454	CcSEcCtD
Melphalan—SLC7A5—Hemostasis—ATP1B2—esophageal cancer	0.00301	0.0129	CbGpPWpGaD
Melphalan—Neoplasm—Methotrexate—esophageal cancer	0.00296	0.00442	CcSEcCtD
Melphalan—Mouth ulceration—Methotrexate—esophageal cancer	0.00296	0.00442	CcSEcCtD
Melphalan—Bladder pain—Methotrexate—esophageal cancer	0.00296	0.00442	CcSEcCtD
Melphalan—Urinary tract disorder—Cisplatin—esophageal cancer	0.00296	0.00442	CcSEcCtD
Melphalan—Liver function test abnormal—Capecitabine—esophageal cancer	0.00295	0.0044	CcSEcCtD
Melphalan—Connective tissue disorder—Cisplatin—esophageal cancer	0.00294	0.0044	CcSEcCtD
Melphalan—Urethral disorder—Cisplatin—esophageal cancer	0.00294	0.00439	CcSEcCtD
Melphalan—Ibuprofen—PTGS1—esophageal cancer	0.0029	0.222	CrCbGaD
Melphalan—Flushing—Cisplatin—esophageal cancer	0.00278	0.00415	CcSEcCtD
Melphalan—SLC7A5—Aryl Hydrocarbon Receptor Pathway—EGFR—esophageal cancer	0.00278	0.0119	CbGpPWpGaD
Melphalan—SLC7A5—Transmembrane transport of small molecules—SLC10A2—esophageal cancer	0.00277	0.0119	CbGpPWpGaD
Melphalan—SLC7A5—Hemostasis—DOCK2—esophageal cancer	0.00272	0.0117	CbGpPWpGaD
Melphalan—Bronchospasm—Capecitabine—esophageal cancer	0.00271	0.00405	CcSEcCtD
Melphalan—Immune system disorder—Cisplatin—esophageal cancer	0.00271	0.00404	CcSEcCtD
Melphalan—Mediastinal disorder—Cisplatin—esophageal cancer	0.0027	0.00403	CcSEcCtD
Melphalan—Arrhythmia—Cisplatin—esophageal cancer	0.00268	0.004	CcSEcCtD
Melphalan—Alopecia—Cisplatin—esophageal cancer	0.00265	0.00396	CcSEcCtD
Melphalan—Pancytopenia—Capecitabine—esophageal cancer	0.00262	0.00391	CcSEcCtD
Melphalan—SLC7A5—Transmembrane transport of small molecules—ATP1B2—esophageal cancer	0.00261	0.0112	CbGpPWpGaD
Melphalan—Neutropenia—Capecitabine—esophageal cancer	0.00258	0.00385	CcSEcCtD
Melphalan—Renal failure acute—Methotrexate—esophageal cancer	0.00257	0.00385	CcSEcCtD
Melphalan—SLC22A3—SLC-mediated transmembrane transport—SLC39A6—esophageal cancer	0.00248	0.0106	CbGpPWpGaD
Melphalan—SLC7A5—Transmembrane transport of small molecules—SLC39A6—esophageal cancer	0.00247	0.0106	CbGpPWpGaD
Melphalan—Neuropathy peripheral—Capecitabine—esophageal cancer	0.00241	0.0036	CcSEcCtD
Melphalan—Anaemia—Cisplatin—esophageal cancer	0.00241	0.0036	CcSEcCtD
Melphalan—Stomatitis—Capecitabine—esophageal cancer	0.0024	0.00358	CcSEcCtD
Melphalan—Jaundice—Capecitabine—esophageal cancer	0.0024	0.00358	CcSEcCtD
Melphalan—SLC7A5—Transmembrane transport of small molecules—AQP3—esophageal cancer	0.00236	0.0101	CbGpPWpGaD
Melphalan—SLC7A5—Hemostasis—PFN1—esophageal cancer	0.00235	0.0101	CbGpPWpGaD
Melphalan—Leukopenia—Cisplatin—esophageal cancer	0.00233	0.00349	CcSEcCtD
Melphalan—Hepatobiliary disease—Capecitabine—esophageal cancer	0.00233	0.00348	CcSEcCtD
Melphalan—SLC22A3—SLC-mediated transmembrane transport—SLC30A7—esophageal cancer	0.00227	0.00974	CbGpPWpGaD
Melphalan—SLC7A5—Transmembrane transport of small molecules—ATP4A—esophageal cancer	0.00226	0.00972	CbGpPWpGaD
Melphalan—SLC7A5—Transmembrane transport of small molecules—SLC30A7—esophageal cancer	0.00226	0.00972	CbGpPWpGaD
Melphalan—Convulsion—Cisplatin—esophageal cancer	0.00226	0.00338	CcSEcCtD
Melphalan—Myalgia—Cisplatin—esophageal cancer	0.00222	0.00332	CcSEcCtD
Melphalan—Haemoglobin—Capecitabine—esophageal cancer	0.00222	0.00332	CcSEcCtD
Melphalan—Hepatitis—Capecitabine—esophageal cancer	0.00221	0.0033	CcSEcCtD
Melphalan—Haemorrhage—Capecitabine—esophageal cancer	0.00221	0.0033	CcSEcCtD
Melphalan—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	0.0022	0.00329	CcSEcCtD
Melphalan—Liver function test abnormal—Methotrexate—esophageal cancer	0.00219	0.00328	CcSEcCtD
Melphalan—Urinary tract disorder—Capecitabine—esophageal cancer	0.00218	0.00326	CcSEcCtD
Melphalan—Connective tissue disorder—Capecitabine—esophageal cancer	0.00217	0.00324	CcSEcCtD
Melphalan—Urethral disorder—Capecitabine—esophageal cancer	0.00216	0.00323	CcSEcCtD
Melphalan—Anaphylactic shock—Cisplatin—esophageal cancer	0.00213	0.00318	CcSEcCtD
Melphalan—Oedema—Cisplatin—esophageal cancer	0.00213	0.00318	CcSEcCtD
Melphalan—Infection—Cisplatin—esophageal cancer	0.00211	0.00316	CcSEcCtD
Melphalan—Thrombocytopenia—Cisplatin—esophageal cancer	0.00208	0.00311	CcSEcCtD
Melphalan—Tachycardia—Cisplatin—esophageal cancer	0.00208	0.0031	CcSEcCtD
Melphalan—Skin disorder—Cisplatin—esophageal cancer	0.00207	0.00309	CcSEcCtD
Melphalan—Flushing—Capecitabine—esophageal cancer	0.00205	0.00306	CcSEcCtD
Melphalan—Anorexia—Cisplatin—esophageal cancer	0.00203	0.00303	CcSEcCtD
Melphalan—Immune system disorder—Capecitabine—esophageal cancer	0.00199	0.00298	CcSEcCtD
Melphalan—Mediastinal disorder—Capecitabine—esophageal cancer	0.00199	0.00297	CcSEcCtD
Melphalan—Hypotension—Cisplatin—esophageal cancer	0.00199	0.00297	CcSEcCtD
Melphalan—Arrhythmia—Capecitabine—esophageal cancer	0.00197	0.00295	CcSEcCtD
Melphalan—Alopecia—Capecitabine—esophageal cancer	0.00195	0.00292	CcSEcCtD
Melphalan—Pancytopenia—Methotrexate—esophageal cancer	0.00195	0.00291	CcSEcCtD
Melphalan—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.00194	0.0029	CcSEcCtD
Melphalan—Neutropenia—Methotrexate—esophageal cancer	0.00192	0.00287	CcSEcCtD
Melphalan—Paraesthesia—Cisplatin—esophageal cancer	0.00191	0.00286	CcSEcCtD
Melphalan—SLC7A5—Hemostasis—CFL1—esophageal cancer	0.00191	0.00819	CbGpPWpGaD
Melphalan—Dyspnoea—Cisplatin—esophageal cancer	0.0019	0.00284	CcSEcCtD
Melphalan—Decreased appetite—Cisplatin—esophageal cancer	0.00185	0.00276	CcSEcCtD
Melphalan—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.00184	0.00275	CcSEcCtD
Melphalan—Pain—Cisplatin—esophageal cancer	0.00182	0.00272	CcSEcCtD
Melphalan—SLC7A5—Hemostasis—GNG7—esophageal cancer	0.0018	0.00772	CbGpPWpGaD
Melphalan—Stomatitis—Methotrexate—esophageal cancer	0.00178	0.00267	CcSEcCtD
Melphalan—Anaemia—Capecitabine—esophageal cancer	0.00178	0.00265	CcSEcCtD
Melphalan—Hepatobiliary disease—Methotrexate—esophageal cancer	0.00173	0.00259	CcSEcCtD
Melphalan—Leukopenia—Capecitabine—esophageal cancer	0.00172	0.00257	CcSEcCtD
Melphalan—SLC7A5—Transmembrane transport of small molecules—ABCC2—esophageal cancer	0.00171	0.00736	CbGpPWpGaD
Melphalan—Cough—Capecitabine—esophageal cancer	0.00168	0.00251	CcSEcCtD
Melphalan—Ibuprofen—PTGS2—esophageal cancer	0.00166	0.127	CrCbGaD
Melphalan—Haemoglobin—Methotrexate—esophageal cancer	0.00165	0.00247	CcSEcCtD
Melphalan—Hepatitis—Methotrexate—esophageal cancer	0.00164	0.00246	CcSEcCtD
Melphalan—Haemorrhage—Methotrexate—esophageal cancer	0.00164	0.00246	CcSEcCtD
Melphalan—Myalgia—Capecitabine—esophageal cancer	0.00164	0.00245	CcSEcCtD
Melphalan—Chest pain—Capecitabine—esophageal cancer	0.00164	0.00245	CcSEcCtD
Melphalan—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	0.00163	0.00243	CcSEcCtD
Melphalan—Urinary tract disorder—Methotrexate—esophageal cancer	0.00162	0.00243	CcSEcCtD
Melphalan—Urethral disorder—Methotrexate—esophageal cancer	0.00161	0.00241	CcSEcCtD
Melphalan—Oedema—Capecitabine—esophageal cancer	0.00157	0.00234	CcSEcCtD
Melphalan—Hypersensitivity—Cisplatin—esophageal cancer	0.00157	0.00234	CcSEcCtD
Melphalan—Infection—Capecitabine—esophageal cancer	0.00156	0.00233	CcSEcCtD
Melphalan—SLC7A5—Transmembrane transport of small molecules—GNG7—esophageal cancer	0.00156	0.00668	CbGpPWpGaD
Melphalan—Thrombocytopenia—Capecitabine—esophageal cancer	0.00154	0.0023	CcSEcCtD
Melphalan—Tachycardia—Capecitabine—esophageal cancer	0.00153	0.00229	CcSEcCtD
Melphalan—Asthenia—Cisplatin—esophageal cancer	0.00153	0.00228	CcSEcCtD
Melphalan—Skin disorder—Capecitabine—esophageal cancer	0.00152	0.00228	CcSEcCtD
Melphalan—Anorexia—Capecitabine—esophageal cancer	0.0015	0.00223	CcSEcCtD
Melphalan—Immune system disorder—Methotrexate—esophageal cancer	0.00148	0.00222	CcSEcCtD
Melphalan—Mediastinal disorder—Methotrexate—esophageal cancer	0.00148	0.00221	CcSEcCtD
Melphalan—Hypotension—Capecitabine—esophageal cancer	0.00147	0.00219	CcSEcCtD
Melphalan—SLC7A5—Hemostasis—HSPA5—esophageal cancer	0.00146	0.00629	CbGpPWpGaD
Melphalan—Diarrhoea—Cisplatin—esophageal cancer	0.00146	0.00218	CcSEcCtD
Melphalan—Alopecia—Methotrexate—esophageal cancer	0.00145	0.00217	CcSEcCtD
Melphalan—Musculoskeletal discomfort—Capecitabine—esophageal cancer	0.00143	0.00214	CcSEcCtD
Melphalan—SLC22A3—Transmembrane transport of small molecules—SLC10A2—esophageal cancer	0.00141	0.00607	CbGpPWpGaD
Melphalan—Paraesthesia—Capecitabine—esophageal cancer	0.00141	0.0021	CcSEcCtD
Melphalan—Ibuprofen—ABCB1—esophageal cancer	0.00141	0.108	CrCbGaD
Melphalan—Dyspnoea—Capecitabine—esophageal cancer	0.0014	0.00209	CcSEcCtD
Melphalan—Dyspepsia—Capecitabine—esophageal cancer	0.00138	0.00206	CcSEcCtD
Melphalan—Decreased appetite—Capecitabine—esophageal cancer	0.00136	0.00204	CcSEcCtD
Melphalan—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.00135	0.00202	CcSEcCtD
Melphalan—Vomiting—Cisplatin—esophageal cancer	0.00135	0.00202	CcSEcCtD
Melphalan—Fatigue—Capecitabine—esophageal cancer	0.00135	0.00202	CcSEcCtD
Melphalan—Rash—Cisplatin—esophageal cancer	0.00134	0.00201	CcSEcCtD
Melphalan—Pain—Capecitabine—esophageal cancer	0.00134	0.002	CcSEcCtD
Melphalan—Dermatitis—Cisplatin—esophageal cancer	0.00134	0.002	CcSEcCtD
Melphalan—SLC22A3—Transmembrane transport of small molecules—ATP1B2—esophageal cancer	0.00133	0.00571	CbGpPWpGaD
Melphalan—Anaemia—Methotrexate—esophageal cancer	0.00132	0.00198	CcSEcCtD
Melphalan—SLC7A5—Cell surface interactions at the vascular wall—PIK3CA—esophageal cancer	0.0013	0.00561	CbGpPWpGaD
Melphalan—Leukopenia—Methotrexate—esophageal cancer	0.00128	0.00191	CcSEcCtD
Melphalan—Nausea—Cisplatin—esophageal cancer	0.00126	0.00189	CcSEcCtD
Melphalan—SLC22A3—Transmembrane transport of small molecules—SLC39A6—esophageal cancer	0.00126	0.00541	CbGpPWpGaD
Melphalan—Cough—Methotrexate—esophageal cancer	0.00125	0.00187	CcSEcCtD
Melphalan—Urticaria—Capecitabine—esophageal cancer	0.00125	0.00186	CcSEcCtD
Melphalan—Convulsion—Methotrexate—esophageal cancer	0.00124	0.00185	CcSEcCtD
Melphalan—Myalgia—Methotrexate—esophageal cancer	0.00122	0.00182	CcSEcCtD
Melphalan—Chest pain—Methotrexate—esophageal cancer	0.00122	0.00182	CcSEcCtD
Melphalan—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	0.00121	0.00181	CcSEcCtD
Melphalan—SLC22A3—Transmembrane transport of small molecules—AQP3—esophageal cancer	0.0012	0.00516	CbGpPWpGaD
Melphalan—Anaphylactic shock—Methotrexate—esophageal cancer	0.00117	0.00175	CcSEcCtD
Melphalan—Infection—Methotrexate—esophageal cancer	0.00116	0.00173	CcSEcCtD
Melphalan—Hypersensitivity—Capecitabine—esophageal cancer	0.00116	0.00173	CcSEcCtD
Melphalan—SLC22A3—Transmembrane transport of small molecules—SLC30A7—esophageal cancer	0.00115	0.00495	CbGpPWpGaD
Melphalan—SLC22A3—Transmembrane transport of small molecules—ATP4A—esophageal cancer	0.00115	0.00495	CbGpPWpGaD
Melphalan—Thrombocytopenia—Methotrexate—esophageal cancer	0.00114	0.00171	CcSEcCtD
Melphalan—Skin disorder—Methotrexate—esophageal cancer	0.00113	0.0017	CcSEcCtD
Melphalan—Asthenia—Capecitabine—esophageal cancer	0.00113	0.00168	CcSEcCtD
Melphalan—Anorexia—Methotrexate—esophageal cancer	0.00111	0.00166	CcSEcCtD
Melphalan—Pruritus—Capecitabine—esophageal cancer	0.00111	0.00166	CcSEcCtD
Melphalan—Hypotension—Methotrexate—esophageal cancer	0.00109	0.00163	CcSEcCtD
Melphalan—SLC7A5—Hemostasis—ABL1—esophageal cancer	0.00108	0.00466	CbGpPWpGaD
Melphalan—Diarrhoea—Capecitabine—esophageal cancer	0.00107	0.0016	CcSEcCtD
Melphalan—Musculoskeletal discomfort—Methotrexate—esophageal cancer	0.00106	0.00159	CcSEcCtD
Melphalan—Paraesthesia—Methotrexate—esophageal cancer	0.00105	0.00157	CcSEcCtD
Melphalan—Dyspnoea—Methotrexate—esophageal cancer	0.00104	0.00156	CcSEcCtD
Melphalan—Dyspepsia—Methotrexate—esophageal cancer	0.00103	0.00154	CcSEcCtD
Melphalan—Decreased appetite—Methotrexate—esophageal cancer	0.00102	0.00152	CcSEcCtD
Melphalan—Gastrointestinal disorder—Methotrexate—esophageal cancer	0.00101	0.00151	CcSEcCtD
Melphalan—Fatigue—Methotrexate—esophageal cancer	0.00101	0.0015	CcSEcCtD
Melphalan—Pain—Methotrexate—esophageal cancer	0.000999	0.00149	CcSEcCtD
Melphalan—Vomiting—Capecitabine—esophageal cancer	0.000997	0.00149	CcSEcCtD
Melphalan—Rash—Capecitabine—esophageal cancer	0.000989	0.00148	CcSEcCtD
Melphalan—Dermatitis—Capecitabine—esophageal cancer	0.000988	0.00148	CcSEcCtD
Melphalan—SLC7A5—Transmembrane transport of small molecules—HMOX1—esophageal cancer	0.000948	0.00407	CbGpPWpGaD
Melphalan—Nausea—Capecitabine—esophageal cancer	0.000932	0.00139	CcSEcCtD
Melphalan—Urticaria—Methotrexate—esophageal cancer	0.000928	0.00139	CcSEcCtD
Melphalan—SLC7A5—Transmembrane transport of small molecules—ABCB1—esophageal cancer	0.000909	0.00391	CbGpPWpGaD
Melphalan—SLC22A3—Transmembrane transport of small molecules—ABCC2—esophageal cancer	0.000873	0.00375	CbGpPWpGaD
Melphalan—Hypersensitivity—Methotrexate—esophageal cancer	0.00086	0.00129	CcSEcCtD
Melphalan—Asthenia—Methotrexate—esophageal cancer	0.000838	0.00125	CcSEcCtD
Melphalan—Pruritus—Methotrexate—esophageal cancer	0.000826	0.00123	CcSEcCtD
Melphalan—Diarrhoea—Methotrexate—esophageal cancer	0.000799	0.00119	CcSEcCtD
Melphalan—SLC22A3—Transmembrane transport of small molecules—GNG7—esophageal cancer	0.000792	0.0034	CbGpPWpGaD
Melphalan—SLC7A5—Hemostasis—NOS2—esophageal cancer	0.000782	0.00336	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—SLC52A3—esophageal cancer	0.000778	0.00334	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—BLVRB—esophageal cancer	0.000778	0.00334	CbGpPWpGaD
Melphalan—Vomiting—Methotrexate—esophageal cancer	0.000743	0.00111	CcSEcCtD
Melphalan—Rash—Methotrexate—esophageal cancer	0.000736	0.0011	CcSEcCtD
Melphalan—Dermatitis—Methotrexate—esophageal cancer	0.000736	0.0011	CcSEcCtD
Melphalan—SLC7A5—Hemostasis—CREBBP—esophageal cancer	0.000702	0.00302	CbGpPWpGaD
Melphalan—Nausea—Methotrexate—esophageal cancer	0.000694	0.00104	CcSEcCtD
Melphalan—SLC22A3—Metabolism—CA1—esophageal cancer	0.000662	0.00284	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—SLC10A2—esophageal cancer	0.000662	0.00284	CbGpPWpGaD
Melphalan—SLC7A5—Hemostasis—NOS3—esophageal cancer	0.000629	0.0027	CbGpPWpGaD
Melphalan—SLC7A5—Transmembrane transport of small molecules—CREBBP—esophageal cancer	0.000608	0.00261	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—CA2—esophageal cancer	0.000605	0.0026	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—ADH7—esophageal cancer	0.000563	0.00242	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—PLCE1—esophageal cancer	0.000563	0.00242	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—ADH1B—esophageal cancer	0.000493	0.00212	CbGpPWpGaD
Melphalan—SLC22A3—Transmembrane transport of small molecules—HMOX1—esophageal cancer	0.000483	0.00207	CbGpPWpGaD
Melphalan—SLC7A5—Hemostasis—EP300—esophageal cancer	0.000478	0.00205	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—TYMP—esophageal cancer	0.000472	0.00203	CbGpPWpGaD
Melphalan—SLC22A3—Transmembrane transport of small molecules—ABCB1—esophageal cancer	0.000463	0.00199	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—CYP26A1—esophageal cancer	0.000459	0.00197	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—ALOX15—esophageal cancer	0.000447	0.00192	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—GSTO1—esophageal cancer	0.000426	0.00183	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—TPI1—esophageal cancer	0.000426	0.00183	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—ALDOB—esophageal cancer	0.000409	0.00176	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—GAPDH—esophageal cancer	0.000394	0.00169	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—CRABP1—esophageal cancer	0.00039	0.00168	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—GNG7—esophageal cancer	0.000371	0.00159	CbGpPWpGaD
Melphalan—SLC7A5—Hemostasis—PIK3CA—esophageal cancer	0.000354	0.00152	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—ALDH2—esophageal cancer	0.000348	0.00149	CbGpPWpGaD
Melphalan—SLC7A5—Hemostasis—TP53—esophageal cancer	0.000342	0.00147	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—GSTT1—esophageal cancer	0.000331	0.00142	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—CYP2A6—esophageal cancer	0.000327	0.0014	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—ENO1—esophageal cancer	0.00031	0.00133	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—PTGS1—esophageal cancer	0.00031	0.00133	CbGpPWpGaD
Melphalan—SLC22A3—Transmembrane transport of small molecules—CREBBP—esophageal cancer	0.00031	0.00133	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—PSME1—esophageal cancer	0.000305	0.00131	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—PSME2—esophageal cancer	0.000305	0.00131	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—CYP1B1—esophageal cancer	0.000263	0.00113	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—CYP19A1—esophageal cancer	0.000248	0.00106	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—HMOX1—esophageal cancer	0.000226	0.000971	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—ABCB1—esophageal cancer	0.000217	0.000932	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—CREBBP—esophageal cancer	0.000145	0.000623	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—NOS3—esophageal cancer	0.00013	0.000558	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—PTGS2—esophageal cancer	0.000119	0.00051	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—EP300—esophageal cancer	9.88e-05	0.000424	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—PIK3CA—esophageal cancer	7.31e-05	0.000314	CbGpPWpGaD
